Clinical Trials Logo

HIV Infections clinical trials

View clinical trials related to HIV Infections.

Filter by:

NCT ID: NCT03408899 Completed - HIV Infections Clinical Trials

Evaluating the Safety and Pharmacokinetics of PC-1005 Administered Rectally to HIV-1 Seronegative Adults

Start date: June 19, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and pharmacokinetics of PC-1005 gel when used as a rectal microbicide in HIV-uninfected men and women (cis or transgender) with a history of consensual receptive anal intercourse.

NCT ID: NCT03408262 Completed - Clinical trials for Human Immunodeficiency Virus

Clinical Trial of HIV Vaccine Combinations in Healthy Men and Women

Ad4HIV
Start date: October 6, 2017
Phase: Phase 1
Study type: Interventional

This is a randomised two-part Phase I study which will explore the impact of different boosting options (MVA-CN54 and recombinant CN54gp140 protein) for oral Adenovirus serotype 4 vector prime expressing HIV-1 CN54 envelope (Ad4-EnvCN54) designed to optimize systemic and mucosal antibody responses. Part 1 is exploratory and designed to select conditions capable of promoting enhanced systemic and mucosal B cell responses in a limited number of participants. Part 2 is dependent upon Part 1 and is designed to study groups selected on performance in part 1 in an expanded number of subjects. Data from both stages will be combined for safety and immunological analyses.

NCT ID: NCT03407105 Completed - Clinical trials for Human Immunodeficiency Virus (HIV)

A Dose-Escalation Study of MDX-010 Administered Monthly as Immunotherapy in Subjects Infected With Human Immunodeficiency Virus (HIV)

Start date: April 21, 2003
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of 2 or 4 doses of MDX-010 in HIV-infected subjects

NCT ID: NCT03403569 Completed - HIV-infection/AIDS Clinical Trials

Safety and Efficacy of Triptolide Wilfordii in New Onset HIV-1 Infection

Start date: September 1, 2018
Phase: Phase 3
Study type: Interventional

The traditional Chinese herbal medicine Triptolide Wilfordii has displayed remarkable effect on the treatment of autoimmune diseases such as rheumatoid arthritis. Now that immunosuppression therapy has recently become a new strategy for HIV infection, it's reasonable to expect the anti-inflammatory effect of Triptolide Wilfordii in HIV infected patients. So we designed a randomized, double-blinded, placebo-controlled study to explore the efficacy and safety of Triptolide Wilfordii in new-onset HIV infection.

NCT ID: NCT03402815 Completed - Inflammation Clinical Trials

Efficacy of Maraviroc in Modulating Atherosclerosis in HIV Patients.

Start date: January 1, 2015
Phase: Phase 4
Study type: Interventional

The investigator tested the efficacy of maraviroc intensification on down-regulating atherosclerotic progression in HIV infected patients with optimal viro-immunologic control and at high cardiovascular risk.

NCT ID: NCT03400293 Completed - HIV Infections Clinical Trials

Real-world Insights of People With Human Immunodeficiency Virus (HIV) Infection

RISE
Start date: January 18, 2018
Phase:
Study type: Observational

This study is designed to identify the burden associated with HIV and its treatment, and assess their health-related quality of life (HRQoL) by measuring key HRQoL domains, including satisfaction with treatment and care, and internalised stigma (ISAT). The study will also explore data for various important subpopulations such as subjects who are virally suppressed; who we anticipate will be the majority of study subjects. The study design is an observational, cross sectional study employing subjects' own mobile phone devices for data entry.

NCT ID: NCT03399903 Completed - HIV-1-infection Clinical Trials

Study of Pentasa® for Reducing Residual Systemic Immune Activation in Treated HIV Infection

Start date: May 1, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

An open label study will be performed on 80 people with HIV infection who are maintained on effective treatment with antiretroviral drugs.

NCT ID: NCT03397420 Completed - HIV Infections Clinical Trials

Family-centered HIV Care, Viral Suppression and Retention in HIV-positive Children, Swaziland

FAM-CARE
Start date: September 13, 2017
Phase: N/A
Study type: Interventional

The study will evaluate the effect of implementing a family-centered care (FAM-CARE) program (where all HIV-positive family members are seen together as a unit and receive care together) on viral suppression and retention in HIV-positive children <15 years through enrollment of a prospective cohort of 660 HIV-positive children and their caregivers at sites that were randomized to either implement the family-care program (intervention sites) or continue the current standard of care (control sites).

NCT ID: NCT03396367 Completed - HIV/AIDS Clinical Trials

Prevention and Risk: Treatment With a New Emphasis on Relationships

PARTNER
Start date: February 14, 2018
Phase: N/A
Study type: Interventional

This research examines the efficacy of an individually-delivered intervention tailored for YMSM in relationships. The intervention - termed PARTNER - utilizes a brief (4 session) motivational interviewing format to target Pre-Exposure Prophylaxis (PrEP) uptake/adherence, HIV transmission risk behavior, and associated drug use.

NCT ID: NCT03394391 Completed - HIV Infections Clinical Trials

The Effectiveness of SMS in Improving Antiretroviral Medication Adherence Among Adolescents Living With HIV in Nigeria

STARTA
Start date: July 5, 2018
Phase: N/A
Study type: Interventional

The non-maintenance of ART adherence is a major barrier to the achievement of optimal treatment outcomes among adolescents living with HIV. ART adherence is a challenge among adolescents living with HIV because of lack of appropriate information, their unique emotional state and lifestyles but the most commonly quoted challenge to adherence is forgetting to take antiretroviral drugs. There is evidence to suggest that short message service (SMS) reminder- interventions may enhance drug compliance among adolescents living with other chronic diseases such as asthma and diabetes. Available literature underscores the need for randomized controlled trials (RCTs) of effective interventions to promote ART adherence among adolescents with HIV. The aim of this study is to evaluate the feasibility, acceptability, and efficacy of interactive and tailored SMS reminders on ART adherence among adolescents (15-19 years) living with HIV in Ogun State, Nigeria. The study hypothesizes that the use of personal mobile phones and SMS reminders for the improvement of ART adherence among adolescents living with HIV are feasible, acceptable, and effective. A single-blind, parallel-design (ratio 1:1), and multi-center RCT of 230 adolescent living with HIV who are non-adherent to medications will be conducted over a one-year period in Southwest Nigeria. All the participants will receive routine adherence counseling during clinic visits and one SMS reminder each for follow-up appointments 48 hours and 24 hours before the follow-up visit date. The intervention group will also receive daily ART adherence reminder SMS. Participants will be assessed at baseline and during follow-up visits at 4, 8, 12, 16 and 20 weeks after the baseline. Baseline assessment of participants will include socio-demographic characteristics; HIV/AIDS risk behaviour assessment, Alcohol and Drug abuse assessment, Client Satisfaction Survey, ART adherence assessment, CD4count and viral load assessments. ART adherence and client satisfaction will be assessed at each follow-up visit while CD4count and viral load assessments will be done at baseline and at 20th week. It is possible that tailored SMS reminders will mitigate the barrier of forgetfulness in ART-adherence and lead to improved drug compliance, viral suppression, and quality of life among adolescents living with HIV.